エッジで生きる: ROS ホメオスタシス がん細胞とその潜在的治療標的
関連する実験動画
Updated: Sep 10, 2025

07:17
Production and Detection of Reactive Oxygen Species ROS in Cancers
Published on: November 21, 2011
70.3K
Noah Brandl1, Rebecca Seitz1, Noah Sendtner1
1Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, Immunology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.
Antioxidants (Basel, Switzerland)
|August 28, 2025
まとめ
癌細胞は 抗酸化物質を利用して 生き延びるのです グルタチオン (GSH) やチオレドキシン (Trx) といったこれらのシステムをターゲットにすることで 酸化還元バランスが乱され 細胞死を誘発することで 癌治療の有望な戦略が提供されます
科学分野:
- レドックス生物学
- 癌の生物学
- 腫瘍学
背景:
- 反応性酸素種 (ROS) は癌において二重の役割を果たし,中程度のレベルでは成長を促進し,高いレベルでは損傷を引き起こす.
- 癌細胞は,酸化ストレスを管理し,酸化還元性ホメオスタシスを維持するために,グルタチオン (GSH),チオレドキシン (Trx),およびスーパーオキシドディスムタゼ (SOD) を含む抗酸化システムに依存しています.
- これらの抗酸化システムは,MAPK/ERK,PI3K/Akt/mTOR,NF-κB,STAT3,およびHIF-1αのような重要ながん信号伝達経路をサポートしています.
研究 の 目的:
- 癌細胞の抗酸化防御メカニズムを標的とした 治療の可能性を探るため
- 癌細胞における酸化還元バランスを薬理学的に調節するための戦略をレビューする.
主な方法:
- フェロプトーシスを誘発するためにアルトレタミンAなどの化合物を用いてグルタチオン系を抑制する.
- PX-12やジメチルフーマレート (DMF) などの薬剤によるチオレドキシン (Trx) システムの障害
- アウラノフィン,ミトマイシンC,ATN-224,およびディスルフィラムなどの化合物を用いてTrx還元酵素とSOD1を抑制する.
主要な成果:
- 脂質過酸化によって引き起こされる細胞死の一種であるフェロプトーシスにつながる.
- Trxシステムを破壊すると,酸化還元感性の生存信号が損なわれ,ミトコンドリア機能障害が促進されます.
- SOD1阻害剤は,腫瘍細胞における酸化ストレスを選択的に強化し,臨床試験におけるいくつかの薬剤を使用しています.
結論:
- 抗酸化システムをターゲットにすることは 腫瘍学における有望な治療戦略です
- レドックスバランスを調節することで 癌の選択的脆弱性を薬理学的に利用できます
- レドックスバランスを 細胞の容認を超えて ターゲットを絞ったがん治療の 合理的なアプローチを提示します
さらに関連する動画
関連する概念動画
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

